BO
BON.F Boiron SA
- Market cap
- EUR 327M
- P/E
- 11.9x
- P/B
- 0.90x
- ROE
- 8.3%
- Dividend yield
- 6.38%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is BON.F undervalued?
Graham numberBON.F trades 30.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Boiron SA fundamental analysis
No fundamental analysis for Boiron SA yet.
Boiron SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Boiron SA
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices (in vitro diagnostics), dietary supplements, herbal remedies, cosmetics, and CBD-based products. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and ac…
Full company profileBoiron SA financial statements
Boiron SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 614M | 618M | 604M | 557M | 514M | 455M | 534M | 493M | 488M | 501M |
| Gross Profit | 489M | 489M | 470M | 430M | 395M | 328M | 380M | 358M | 359M | 366M |
| Operating Income | 129M | 122M | 99.1M | 71.5M | 69.7M | 39.5M | 55.5M | 40.8M | 35.8M | 36.4M |
| EBITDA | - | 155M | 141M | 105M | 107M | 64.6M | 77.0M | 73.7M | 58.2M | 62.6M |
| Net Income | 77.7M | 78.2M | 57.5M | 40.6M | 26.2M | 28.6M | 44.7M | 35.8M | 11.3M | 32.6M |
| EPS | - | 4.25 | 3.28 | 2.32 | 1.50 | 1.63 | 2.57 | 2.06 | 0.65 | 1.88 |
| Balance Sheet | ||||||||||
| Total Assets | 755M | 800M | 767M | 764M | 782M | 771M | 789M | 590M | 576M | 603M |
| Total Liabilities | 285M | 283M | 281M | 259M | 273M | 239M | 232M | 199M | 198M | 210M |
| Shareholders' Equity | 470M | 517M | 486M | 505M | 509M | 532M | 558M | 394M | 378M | 393M |
| Cash & Short-term Investments | 244M | 275M | 217M | 208M | 235M | 235M | 251M | 74.0M | 64.7M | 79.3M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 110M | 105M | 84.3M | 50.9M | 68.3M | 33.3M | 58.7M | 45.5M | 39.5M | 53.2M |
| Capital Expenditure | 27.8M | 45.3M | 40.9M | 26.5M | 10.7M | 11.0M | 18.6M | 18.0M | 15.9M | 23.5M |
| Free Cash Flow | - | 51.4M | 36.6M | 13.3M | 47.6M | 12.9M | 40.1M | 27.5M | 23.6M | 29.7M |
| Ratios | ||||||||||
| ROE | 16.6% | 15.1% | 11.8% | 8.0% | 5.1% | 5.4% | 8.0% | 9.1% | 3.0% | 8.3% |
| ROA | 10.3% | 9.8% | 7.5% | 5.3% | 3.4% | 3.7% | 5.7% | 6.1% | 2.0% | 5.4% |
| Net Profit Margin | 12.6% | 12.7% | 9.5% | 7.3% | 5.1% | 6.3% | 8.4% | 7.3% | 2.3% | 6.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Boiron SA dividends
- Dividend yield
- 6.38%
- Forward dividend
- 1.35 EUR
- Payout ratio
- 63.8%
- Ex-dividend date
- Jun 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 20.8M | 1.20 | 63.8% |
| 2024 | EUR 23.4M | 1.35 | 206.8% |
| 2023 | EUR 199M | 11 | 555.4% |
| 2022 | EUR 16.5M | 0.95 | 36.9% |
| 2021 | EUR 16.6M | 0.95 | 58.3% |
| 2020 | EUR 18.4M | 1.05 | 70.1% |
| 2019 | EUR 25.4M | 1.45 | 62.5% |
| 2018 | EUR 28.3M | 1.62 | 49.3% |
| 2017 | EUR 29.5M | 1.60 | 37.7% |
| 2016 | EUR 27.6M | - | 35.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 4:1 on Jul 1, 2003.
Who owns Boiron SA
- Insiders 86.11%
- Institutions 4.85%
- Public & others 9.04%
- Shares outstanding 17.4M
- Free float 2.25M
Boiron SA company profile
- Company name
- Boiron SA
- Ticker
- BON.F
- ISIN
- FR0000061129
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,623
- Fiscal year end
- December
- Address
- 2, avenue de l?Ouest Lyonnais, Messimy, France, 69510
- Phone
- 33 4 78 45 61 00
- Website
- boiron.fr
About Boiron SA
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices (in vitro diagnostics), dietary supplements, herbal remedies, cosmetics, and CBD-based products. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sedative PC Granules to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. Further, the company provides Quietude, Rhinallergy, Ribes Nigrum Macerate Glycerin 1 DH Boiron, Sabal serrulata Mother Tincture Boiron, Sevameo, Sinupyl, Sportenine, Stodaline Sugar-Free, Stodal Granules, Stodal Syrup, Storinyl, Sedative PC Sublingual Tablet, Tilia Tomentosa Glycerinated Macerate 1DH Boiron, Varesol, Verrulia, Avenoc Suppository, Calendula Cream, Zelaceo, and Zenalia. It offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is based in Messimy, France.
Boiron SA management
8- Mr. Thierry BoironDeputy GM & Director · born 1961
- Mr. Fabrice ReyGroup Treasurer
- Mr. Pascal HoudayerGM & Director · born 1969
- Mr. Patrice VarrautDirector of Operations
- Julien NavarraLegal Director
- Gregoire BalayMarketing Director
- Ms. Juliette BaudryHuman Resources Director
- Mr. Eric LambertSecretary General